The protective effects and potential mechanism of Calpain inhibitor Calpeptin against focal cerebral ischemia-reperfusion injury in rats.
To demonstrate the protective effects of Calpeptin as the Calpain inhibitor against focal cerebral ischemia-reperfusion injury in rats and to explore it's possible mechanism. 96 rats were randomly divided into four groups. The model of middle cerebral artery occlusion was used for the research of focal cerebral ischemia. Using this animal model, the effects of Calpeptin on the neurological functions, infarction volume and infarction volume percentage of brain, Caspase-3 expression and neuronal apoptosis in hippocampal CA1 sector after focal cerebral ischemia-reperfusion injury in rats were investigated. The current results confirmed that Calpeptin as the Calpain inhibitor might paly an important role for neuroprotection against focal cerebral ischemia-reperfusion injury. Calpeptin could reduce the neuronal apoptosis in hippocampal CA1 sector when the rats was subjected to the focal cerebral ischemia-reperfusion, the potential mechanism might be related to the inhibition of the expression of Caspase-3 by Calpeptin. However, it is still unknown to what the exact mechanism of Calpeptin inhibits the activation of Caspase-3 in this process. Therefore, further research needs to be done to unravel the underlying mechanisms in the future.
Peng
Sheng
S
Department of Anesthesiology, Affiliated No. 4 Hospital of Soochow University, Wuxi, 214062, People's Republic of China.
Kuang
Zhongshen
Z
Zhang
Yan
Y
Xu
Hang
H
Cheng
Qinghong
Q
D000818:Animals; D017209:Apoptosis; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D053148:Caspase 3 / Q000096:biosynthesis; D002544:Cerebral Infarction / Q000188:drug therapy*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004151:Dipeptides / Q000737:chemistry* / Q000494:pharmacology; D006624:Hippocampus / Q000378:metabolism; D007150:Immunohistochemistry / Q000379:methods; D020287:In Situ Nick-End Labeling; D008297:Male; D009474:Neurons / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy*; D013778:Tetrazolium Salts / Q000494:pharmacology
D015853:Cysteine Proteinase Inhibitors; D004151:Dipeptides; D013778:Tetrazolium Salts; C071482:calpeptin; C009591:triphenyltetrazolium; D053148:Caspase 3
J Biol Chem. 2005 Apr 15;280(15):15229-37
15699033
Mol Biol Rep. 2010 Jan;37(1):269-72
19669932
Mol Biol Rep. 2011 Jun;38(5):3037-44
20127518
Hippocampus. 2003;13(7):791-800
14620874
Stroke. 1998 Jan;29(1):152-8
9445345
Nature. 1999 Jun 24;399(6738 Suppl):A7-14
10392575
Mol Biol Rep. 2008 Jun;35(2):119-23
17431820
Endocrinology. 2002 Apr;143(4):1386-403
11897696
Circulation. 2001 Apr 24;103(16):2035-7
11319190
Stroke. 1989 Jan;20(1):84-91
2643202
Stroke. 1986 May-Jun;17(3):472-6
3715945
J Cell Biochem. 2000 Sep 18;80(1):53-72
11029754
J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S225-7
11078383
Brain Res. 2000 Jun 2;866(1-2):299-312
10825507
Brain Res. 1998 Apr 20;790(1-2):1-13
9593800
J Biol Chem. 2001 Mar 30;276(13):10191-8
11124942
J Biol Chem. 2005 Jun 3;280(22):21588-93
15790561
Mol Biol Rep. 2010 Jun;37(5):2439-46
19693689
Neurosci Biobehav Rev. 1997 Mar;21(2):121-8
9062934
Mol Biol Rep. 2010 Dec;37(8):3763-9
20217242
J Neurosci Res. 2005 Aug 15;81(4):551-62
15968645
Neurol Res. 2001 Jul;23(5):522-30
11474809
Eur J Neurosci. 1998 May;10(5):1723-33
9751144
Mol Biol Rep. 2011 Jun;38(5):3235-42
20182801
Int J Mol Med. 2003 Mar;11(3):369-74
12579342
J Neurosci. 1995 Feb;15(2):1001-11
7869078
Stroke. 1996 Sep;27(9):1616-22; discussion 1623
8784138
Mol Biol Rep. 2010 Mar;37(3):1467-75
19434514